6th Annual Medical Device Investor Forum
Hyatt Regency Irvine
17900 Jamboree Road
Irvine, California, USA 92614
November 15, 2011
4:50 pm PST

(ONCS.OB) OncoSec Medical Incorporated will be presenting at the 6th Annual Medical Device Investor Forum in Irvine, California

About OncoSec Medical Incorporated (OTCBB:ONCS)

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy. More information is available at www.oncosec.com.

OncoSec Medical Incorporated Trading Symbols

OncoSec Medical Incorporated trades Over The Counter As ONCS (OTCBB:ONCS, ONCS.OB, ONCS.OTCBB, ONCS, ONCS.OTCQB)

About PublicWire.com

PublicWire.com is a Small Cap Financial Press Release Company that uses a variety of cutting edge methods to syndicate your Small Cap Press Release to various news and information outlets. Our press releases have consitantly placed the Small Cap Companies we work with on the first result page of major search engines such as Google, Bing, and Yahoo. We work exclusively with Pinksheet and Over The Counter (PK and OTCBB) Companies to ensure maximum exposure for their Press Releases.

To maximize your OTCBB / Pinksheet / Small Cap Company Press Release, call us directly at 407-218-7446.

OTCBB:ONCS, ONCS.OB, ONCS.OTCBB, ONCS, ONCS.OTCQB

The symbols “OTCBB:ONCS, ONCS.OB, ONCS.OTCBB, ONCS, ONCS.OTCQB” reflect the variety of methods OncoSec Medical Incorporated lists their stock as, and were valid at the time of original publication of this press release.

Applied DNA provides DNA markers to protect cash and valuables in transit (CViT), to protectbrand owners, and to secure legitimate supply chains against the diversion to gray markets and against the infiltration of counterfeit products. The company’s approach to each vertical market has been to sell its unique, uncopyable DNA tags to suppliers whose components enter at the bottom or through multiple points within a supply chain, and then license the platform to “pain
points” that experience the most liability.

Licensing Model Similar to Software Industry

For example, within the cash transportation industry, APDN sells its DNA markers to the security ink users, ATM cassette manufacturers, and cash box manufacturers, who supply their DNA-enhanced products to security companies and ATM owners. However, the security value in the event of theft can only be realized if the risk-owner has licensed the platform from APDN.

License Unlocks the DNA Sequence Key

“Our model is similar to that employed by the software industry,” said Dr. James Hayward, CEO of APDN. “We ensure widespread deployment of our DNA marks within an industry, in the same manner as software developers distribute software via laptops and device manufacturers. Our licensees can only realize the value of the DNA markers, just as software must be licensed to enjoy its value.” He continued: “Our DNA sequence content is only available to our licensees.
We maintain control of our sequences, and only we can authenticate the cash stolen and provide forensic support in an act perpetrated against a risk-owner, which is initially the cash-intransit transporter, but ultimately includes the financial institution and their insurer.”

APDN now has a proven track record within the CViT industry. With over 22 convictions to its credit, APDN has a 100% conviction record for captured criminals who have stolen cash from its security licensees within the UK. The result, the deterrence provided by APDN, yielded a significant drop in attacks and eliminated cash losses more than one hundred times the cost of annual licensing.

Proven Return on Investment

This proven ROI has brought APDN customers higher up the risk chain. “Banks, insurers and governments are now recognizing the deterrence that can only be provided by DNA markers,” said Dr. Hayward. “We have received initial orders from governments and insurers, and we are fielding inquiries from banks internationally. The increased demand contributed to the closing of the best quarter in our company’s history, announced in SEC filings that describe our first FY11 quarter, ending December 2010.”

About APDN

APDN sells patented DNA security solutions that provide anti-counterfeit protection, as well as protecting brands and intellectual property from counterfeiting and diversion. SigNature DNA is a botanical mark used for product authentication in a unique manner that essentially cannot be copied. When used in conjunction with other law enforcement technologies, SigNature DNA can provide a forensic chain of evidence that has been used successfully in more than 22 convictions. To learn more, go to www.adnas.com where APDN routinely posts all press releases.

The statements made by APDN may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to ur short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K, filed on December 15, 2010 and our subsequent quarterly reports on Form 10-Q. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.

SOURCE Applied DNA Sciences, Inc.
INVESTOR CONTACT: Debbie Bailey, 631-444-8090, fax: 631-444-8848
MEDIA CONTACT: Janice Meraglia, 631-444-6293, fax: 631-444-8848
FCMN Contact: info@adnas.com
Web site: http://www.adnas.com

Trading Symbols

Applied DNA Sciences trades Over The Counter As APDN (OTCBB:APDN, APDN.OB, APDN.OTCBB, APDN)

About PublicWire.com

PublicWire.com is a Small Cap Financial Press Release Company that uses a variety of cutting edge methods to syndicate your Small Cap Press Release to various news and information outlets. Our press releases have consitantly placed the Small Cap Companies we work with on the first result page of major search engines such as Google, Bing, and Yahoo. We work exclusively with Pinksheet and Over The Counter (PK and OTCBB) Companies to ensure maximum exposure for their Press Releases.

To maximize your OTCBB / Pinksheet / Small Cap Company Press Release, call us directly at 407-218-7446.

OTCBB:APDN, APDN.OB, APDN.OTCBB, APDN

The symbols “OTCBB:APDN, APDN.OB, APDN.OTCBB, APDN” reflect the variety of methods APDN lists their stock as, and were valid at the time of original publication of this press release.

An independent Stem Cell Research Oversight (SCRO) committee approved ISCO’s program to obtain human oocytes (eggs) in California. The independent SCRO committee is responsible for reviewing the scientific rationale, ethics and compliance with State and Federal regulations and guidelines for studies involving human stem cells. This approval in combination with the earlier reported Institutional Review Board (IRB) clearance with regard to medical safety opens the way for ISCO’s stem cell banking program to begin registering clinical investigators. ISCO’s study is designed to produce new clinical-grade human parthenogenetic stem cell lines that can be immune matched to millions of individuals for use in the emerging field of regenerative medicine.

ISCO’s breakthrough discoveries have resulted in unique stem cells carrying distinct advantages over other human pluripotent stem cells. ISCO uses unfertilized oocytes to create human “parthenogenetic” stem cells (hpSCs). Like human embryonic stem cells (hESCs), hpSCs are pluripotent, i.e. they have the capacity to become almost any cell type in the body, yet avoid ethical issues associated with use or destruction of viable human embryos. Unlike hESCs, hpSCs can be created in a form such that they can be immunologically matched to millions of individuals.

About ISCO

Currently ISCO has a collection of ten hpSC lines that are shared with collaborators and used for research purposes. Although these ten stem cell lines conform to all relevant US standards, they were derived outside the United States. New cell lines created under this study will be ISCO’s first hpSC to be produced in the United States. ISCO’s scientists, leaders the field of creating therapeutic cells from hpSC, will work with these lines targeting new treatments for human diseases. The company will also share these cells with other scientists to further clinical research. ISCO intends to derive and store these cells at its Oceanside facilities, which are designed to create cells suitable for clinical use.

Simon Craw, PhD, says, “These approvals, combined with our technology, make the establishment of a bank of immune matched stem cells practical and allow for the possibility of cell-based therapy to be economic for millions of people. We believe we are one of the first commercial entities in the United States to have progressed to this point.”

Trading Symbols

International Stem Cell Corporation trades Over The Counter As ISCO (OTCBB:ISCO, ISCO.OB, ISCO.OTCBB, ISCO)

About PublicWire.com

PublicWire.com is a Small Cap Financial Press Release Company that uses a variety of cutting edge methods to syndicate your Small Cap Press Release to various news and information outlets. Our press releases have consitantly placed the Small Cap Companies we work with on the first result page of major search engines such as Google, Bing, and Yahoo. We work exclusively with Pinksheet and Over The Counter (PK and OTCBB) Companies to ensure maximum exposure for their Press Releases.

To maximize your OTCBB / Pinksheet / Small Cap Company Press Release, call us directly at 407-218-7446.

OTCBB:ISCO, ISCO.OB, ISCO.OTCBB, ISCO

The symbols “OTCBB:ISCO, ISCO.OB, ISCO.OTCBB, ISCO” reflect the variety of methods lists their stock as, and were valid at the time of original publication of this press release.

The article headlined, “New Drug Delivery Device Will Speed Up Numbing, Sans Needle,” notes that the Prelude System “promises to speed up the effects of lidocaine, a topical anesthetic, so shots, IVs, and other medical procedures will be less painful.”

“We are pleased to have our technology featured by Fast Company magazine and to have Prelude’s needle-free drug delivery benefits explained so clearly to its influential readership,” stated Patrick T. Mooney, MD, Chairman and CEO of Echo Therapeutics. “Building on the positive momentum we have generated through much hard work, we are excited to increase the visibility of our needle-free platform technology as we near potential FDA marketing clearance.”

The article also discussed the positive attributes for diabetics of Echo’s Symphony System’s non-invasive, wireless continuous transdermal glucose monitoring technology.

Fast Company magazine and Fastcompany.com are widely read business publications that cover innovation, technology and leadership, written by and for the most progressive business leaders.

About ECTE: Echo Therapeutics has developed a platform technology for needle-free drug delivery as well as needle-free, continuous glucose monitoring. It is developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals. Echo is also developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units.

(ECTE.OB) Therapeutics, Inc. Has Prelude System Featured on Fast Company Website

For all the latest in small cap news, videos, and information, or to submit your own press release through PublicWire.com, visit us online at PublicWire.com, or call us 407-218-7446.

ECTE.OB, ECTE.OTCBB, OTCBB:ECTE, ECTE

Bioject’s ID Pen spring-powered needle-free injector, currently under development and not yet cleared by the FDA, is intended to be used for intradermal injections for vaccinations and drug therapy. The system consists of a hand-held, user-filled device that incorporates single-use, auto-disable disposable syringes. The molded syringes have orifices about the thickness of a human hair, through which the liquid drug is forced into the skin. The ID Pen is designed to deliver .05 mL or .10 mL for each injection. The injector is entirely mechanical and is intended for administration by trained health workers.

For some vaccines, ID vaccine delivery can achieve the same results as an intramuscular or subcutaneous injection–fully immunizing beneficiaries but using up to 80 percent less vaccine. Reduced dosage is appealing to immunization programs because it has the potential to simultaneously increase vaccine availability and decrease costs associated with vaccine delivery. Since accurate and reliable ID delivery is difficult to ensure, particularly in low-resource settings, new delivery technologies like Bioject’s ID Pen injector may make the method more appropriate for use in the developing world. This could result in more children being vaccinated, particularly in developing countries. The ID Pen is intended to improve the safety and ease of ID delivery of vaccines and could enable immunization programs to stretch their vaccine supplies across a larger number of beneficiaries.

This collaboration is part of ongoing research by the Global Polio Eradication Initiative (GPEI) to prepare for the post-eradication era of polio, a disease slated for worldwide eradication in the near term. For countries that perceive that the risks warrant continued immunization against polio after eradication, inactivated polio vaccine (IPV) is currently the only option with which to do this, and the GPEI is studying a range of approaches to establish affordable strategies for IPV use in low-income settings. WHO, PATH, and Bioject recently collaborated on a research study on fractional doses of IPV delivered intradermally using the Biojector(R) 2000 to infants in Oman. The study results were published in 2010 in The New England Journal of Medicine and showed successful ID administration in addition to potential cost savings of the fractional dose when compared to the cost of full-dose vaccination using a traditional needle and syringe. The hope is that this new device could make IPV affordable for developing-country use and stretch the limited supply of IPV, crucial for polio post-eradication planning. At the same time, it could go a long way to getting rid of needles altogether in routine immunization programs.

“We are very excited to enter into this new collaboration, which advances the development of a new state-of-art needle-free ID Pen injector, especially after learning of the exciting study results reported in the New England Journal of Medicine using our established B2000 device to investigate intradermal delivery of polio vaccine. This new ID Pen injector will provide the needed technology for delivery of vaccines and drugs using the intradermal approach and perhaps allow a dose sparing effect,” said Dr. Richard Stout, Bioject’s Executive Vice President and Chief Medical Officer. “We appreciate the leadership, support and foresight of our collaborators to help bring this innovative technology to patients, caregivers, and the global medical community,” commented Dr. Stout.

PATH is working to expand access to vaccines by those who need them most. This work will help advance the class of needle-free injection technologies for developing-country immunization programs and contribute to a body of work that improves vaccine delivery safety. DSJIs eliminate the risk of needle reuse and needlestick injuries, and PATH is conducting a cost-modeling analysis to see how costs to immunization programs compare with traditional needle and syringe. PATH is also comparing general acceptability of these alternative devices with typical administration practices and testing effectiveness for delivery of certain vaccines.

(BJCT.OB) Bioject Medical Technologies Inc. Delivers Intradermal Pen To WHO

For all the latest in small cap news, videos, and information, or to submit your own press release through PublicWire.com, visit us online at PublicWire.com, or call us 407-218-7446.

BJCT.OB, BJCT.OTCBB, OTCBB:BJCT, BJCT

As a result of these additions, Bohai’s board now has six members, four of whom are independent as defined by SEC and NASDAQ rules.

Mr. Chan brings nearly 30 years of experience in finance and management to Bohai. He has been instrumentally involved with multiple PIPEs, mergers, IPO’s and investment transactions, specifically involving U.S.-listed Chinese companies. He currently serves as Chief Financial Officer at a leading Chinese mobile phone manufacturer, Zoom Technologies, Inc. (Nasdaq: ZOOM). Previously, Mr. Chan served as an Asia Investment Banking Consultant to GunnAllen Financial, Inc., Chief Financial Officer and Director of the Board of a US internet technology company, hereUare, Inc. and served as a financial advisor and CEO at two other NASDAQ listed US and Chinese companies.

“With his strong management background and multiple years of experience as CFO of several US-listed public companies, I am delighted to have Mr. Chan join Bohai’s Board of Directors, along with our CFO, Gene Hsiao,” said Mr. Hongwei Qu, Chairman, President and Chief Executive Officer of Bohai Pharmaceuticals. “We are looking forward to working with Mr. Chan and believe his execution in financial transaction skill-set will prove extremely valuable in helping to guide Bohai’s expansion in the years ahead. As we continue to strengthen our Board, Mr. Chan’s and Mr. Hsiao’s appointments take us one step closer to our goal of uplisting to NASDAQ.”

Gene Hsiao joined Bohai as Chief Financial Officer in June 2010. He has over 15 years of SEC accounting, corporate finance and public company management experience. Since joining the company, Mr. Hsiao has overseen all of Bohai’s financial reporting and related company procedures, has taken a lead role in Bohai’s investor relations program, and is spearheading the company’s move towards an uplisting to NASDAQ.

Bohai also announced that it has formally established three independent board committees – an audit committee, nominating and corporate governance committee and compensation committee. The formation of these committees is a requirement for uplisting to NASDAQ, and the company will look to the expertise and guidance of its independent directors serving on these committees to further enhance Bohai’s corporate governance.

(BOPH.OB) Bohai Pharmaceuticals Group, Inc. Appoints New Independent Director

For all the latest in small cap news, videos, and information, visit us online at PublicWire.com, or call us407-218-7446.

BOPH.OB, BOPH.OTCBB, OTCBB:BOPH, BOPH

“We are honored to welcome Dr. Ricordi to our Medical Advisory Board, and are confident that his background and experience in diabetes research will prove invaluable to the Company,” said Michael McCarthy, president and CEO of NXT Nutritionals. “Dr. Ricordi has earned the highest honors in his field, and we look forward to working with him on initiatives designed especially for people with diabetes and people eager to remove excess sugars from their diets.”

A leading expert in pancreatic islet transplantation, Dr. Ricordi is the Stacy Joy Goodman Professor of Surgery, Distinguished Professor of Medicine, Professor of Biomedical Engineering, and Microbiology and Immunology at the University of Miami Diabetes Research Institute. He also serves as Director of the Diabetes Research Institute Cell Transplant Center and Responsible Head of the cGMP Human Cell Processing Facility, a NIH-funded facility.

“I am pleased to be joining NXT Nutritionals’ Medical Advisory Board to help consumers learn about SUSTA, a groundbreaking, all-natural sugar alternative that is safe for people with diabetes,” said Dr. Ricordi. “The Company understands the importance of presenting alternatives to dietary sugars in order to begin to curb the country’s burgeoning diabetes epidemic, and I am thrilled to be a part of their efforts.”

Among his many accomplishments, Dr. Ricordi has served as President of the Cell Transplant Society, Co-founder and Chairman of the National Diabetes Research Coalition, Co-founder and President of the International Association for Pancreas and Islet Transplantation and a member of the council of The Transplantation Society. He has authored over 600 scientific publications and has been awarded 11 patents as an inventor. Dr. Ricordi completed his graduate and post-graduate studies at the University of Milan, Italy and Università degli Studi di Milano.

About NXT Nutritionals Holdings, Inc.

Headquartered in Holyoke, MA, NXT Nutritionals Holdings, Inc., through its wholly owned subsidiary NXT Nutritionals, Inc., is a developer and marketer of a proprietary, patent-pending, all–natural, healthy sweetener sold under the brand name SUSTA™ and other food and beverage products. SUSTA™ Natural Sweetener, sold as a stand-alone product and the common ingredient for all of the Company’s products, is an all-natural, healthy sweetener that has minimal calories and low glycemic index. NXT Nutritionals has also developed a line of SUSTA™-enhanced best-in-class, non-fat reduced-calorie yogurt smoothies that are marketed as Healthy Dairy® Yogurt Smoothies. For additional information, please visit NXT Nutritionals’ corporate website:

www.nxtnutritionals.com

Forward-Looking Statements

The statements in the press release that relate to the Company’s expectations with regard to the future impact on the Company’s results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties. Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of NXT Nutritionals Holdings, Inc. can be found in the filings of NXT Nutritionals Holdings, Inc. with the U.S. Securities and Exchange Commission.

Contact:

NXT Nutritionals Holdings, Inc.

Michael McCarthy, 1-800-535-4315

President and CEO

moreinfo@nxtnutritionals.com

(NXTH.OB)NXT Nutritionals Appoints Leading Diabetes Expert Camillo Ricordi, M.D., to Its Medical Advisory Board

For all the latest in small cap news, videos, and information, visit us online at PublicWire.com, or call us at 407-218-7445.

NXTH, NXTH.OB, NXTH.OTCBB, OTCBB:NXTH

Furthermore, American HomePatient (with the consent of Highland Capital Management, L.P. (”Highland”)) is modifying the tender offer condition that the number of shares tendered, when added to the number of shares owned by Highland and its affiliates, constitutes at least 90% of the then outstanding shares of common stock (the “Minimum Condition”). Instead of 90%, the Minimum Condition will now be satisfied if the number of shares tendered, when added to the number of shares owned by Highland and its affiliates, constitutes at least 80% of the then outstanding shares of common stock.

As of the close of business on August 25, 2010, 6,896,041 shares of common stock had been tendered in and not withdrawn from the offer. These tendered shares, when added to the number of shares owned by Highland and its affiliates, constitute approximately 87% of the outstanding shares of common stock.

(AHOM.OB) ;American HomePatient, Inc. Extends Self-Tender Offer For All Outstanding Shares Of Common Stock

AHOM.OB, AHOM.OTCBB, OTCBB:AHOM, AHOM

For more information, and to be better informed in your decision making process, check out a detailed profle of AHOM’s perfomance.

Forward Looking Statements

Certain statements in this press release that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as “anticipate, “believe,” “expect,” “future,” “may,” “will,” “would,” “should,” “plan,” “projected,” “potential,” “intend,” and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the “company to be materially different from those expressed or implied by such forward-looking statements.

For all the latest in small cap news, videos, and information, visit us online at PublicWire.com, or call us, toll free, at 888-843-1412.

The Company has received a funding commitment from a European consortium of institutional investors that has agreed to invest up to $7.5 million into ActiveCare, at a price of $0.75 per share; the immediate funding of $2.5 million will be received by the Company within thirty days. Future tranches will be available at the option of the Company, dependent upon the achievement of certain milestones in the level of members using the Company’s products. The commitment also requires that the Company’s preferred shareholders convert their preferred shares into common stock at a price of $1 per share and that the warrants held by these shareholders be re-priced at $1 per share with no future re-sets.

As additional conditions to the commitment, the consortium will have the right to appoint two non-executive board members to ActiveCare’s board of directors.

With the initial funding complete the Company will have the capital necessary to perform on its business plan and fulfill orders for its products and services. In addition, the arrangement with the preferred shareholders will eliminate a $2,000,000 liability associated with a mandatory redemption provision imbedded in the Preferred Shares.

“This funding commitment will allow the Company to achieve its goals and projections and allows ActiveCare to implement its marketing and manufacturing requirements for more than 5,000 members,” stated James Dalton, president.

(ACAR.OB) ActiveCare, Inc. Announces Capital Raise Commitment And Balance Sheet Restructuring

About ActiveCare

ActiveCare (website at www.activecare.com) is a leading edge telematic and biosensor technology company that can provide “peace of mind” to both the care provider and the senior and ensures that the senior’s health needs are being met. Through ActiveCare’s CareCenter(TM) the member’s medical data are stored, including doctors, medications and care providers. In addition through its telematic technologies, it constantly knows where the member is located in case of an emergency and at the touch of button is in immediate contact with a CareSpecialist(TM). Through the ongoing development of ActiveCare’s nano biosensors, combined with its telematics devices, the CareCenter will be able to constantly monitor physiological trends that insure the member is complying with his medications and avoids unacceptable levels of drug toxicity. It does all of this while allowing the senior to live an active and independent life, and at the same time save the health care system millions of dollars.

ACAR.OB, ACAR.OTCBB, OTCBB:ACAR, ACAR

For more information, and to be better informed in your decision making process, check out a detailed profle of ACAR’s perfomance.

Forward Looking Statements

Certain statements in this press release that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as “anticipate, “believe,” “expect,” “future,” “may,” “will,” “would,” “should,” “plan,” “projected,” “potential,” “intend,” and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the “company to be materially different from those expressed or implied by such forward-looking statements.

For all the latest in small cap news, videos, and information, visit us online at PublicWire.com, or call us, toll free, at 888-843-1412.

Patrick Rooney, chief executive officer of Positron Corporation, will be presenting on Tuesday, September 14th. Details surrounding the presentation and audio webcast will be made available in the coming weeks.

For more information about the Rodman & Renshaw 12th Annual Healthcare Conference, go to: http://www.rodmanandrenshaw.com/conferences.

(POSC.OB) Positron Corporation Is Scheduled To Present At Rodman & Renshaw Annual Global Investment Conference

About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution. Positron products include: the Attrius, a PET imaging device; the Pulse , a SPECT imaging device; the Nuclear Pharm-Assist , an automated radiopharmaceutical distribution device; and the Tech-Assist, a radiopharmaceutical injection shield. More information about Positron is available at www.positron.com.

POSC.OB, POSC.OTCBB, OTCBB:POSC, POSC

For more information, and to be better informed in your decision making process, check out a detailed profle of POSC’s perfomance.

Forward Looking Statements

Certain statements in this press release that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as “anticipate, “believe,” “expect,” “future,” “may,” “will,” “would,” “should,” “plan,” “projected,” “potential,” “intend,” and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the “company to be materially different from those expressed or implied by such forward-looking statements.

For all the latest in small cap news, videos, and information, visit us online at PublicWire.com, or call us, toll free, at 888-843-1412.